IDEAYA Biosciences Appoints Darrin Beaupre As Chief Medical Officer

RTTNews | 961 days ago
IDEAYA Biosciences Appoints Darrin Beaupre As Chief Medical Officer

(RTTNews) - Oncology company IDEAYA Biosciences, Inc. (IDYA) announced that Darrin Beaupre has joined the company as its Chief Medical Officer, effective November 21, 2022.

Beaupre's extensive career includes various clinical development and translational research roles in industry, including most recently at BioSplice Therapeutics as Chief Medical Officer and Head of Research and Development in Oncology.

Beaupre previously served as Senior Vice President, Head of Early Oncology Development and Clinical Research at Pfizer, Inc., where he led cross-disciplinary groups including clinical development, clinical pharmacology, translational oncology and clinical operations related study clinicians.

Beaupre also served at Pharmacyclics (Abbvie) as Vice President, Head of Early Development and Immunotherapy, and at Amgen as Medical Director.

He was previously an Assistant Professor at the H. Lee Moffitt Cancer Center and Research Institute, and also held various earlier appointments at the University of Miami and the M.D. Anderson Cancer Center.

read more
IDEAYA Biosciences Q4 Results Misses Estimates

IDEAYA Biosciences Q4 Results Misses Estimates

IDEAYA Biosciences, Inc. (IDYA), a precision medicine oncology company, announced net loss of $32.64 million or $0.52 per share, wider than $23.07 million or $0.50 per share in the prior-year quarter.
RTTNews | 512 days ago
IDEAYA Biosciences Says FDA Clears IND For Pol Theta Helicase Development Candidate GSK101

IDEAYA Biosciences Says FDA Clears IND For Pol Theta Helicase Development Candidate GSK101

Oncology company IDEAYA Biosciences, Inc. (IDYA) announced Monday the clearance of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for initiation of a GSK-sponsored Phase 1/2 clinical trial to evaluate GSK101 (IDE705) for the treatment of patients having tumors with BRCA or other homologous recombination (HR) mutations or homologous recombination deficiency (HRD).
RTTNews | 695 days ago
Swiss Market Ends Slightly Up

Swiss Market Ends Slightly Up

After a choppy ride till around noon, Swiss stocks gained in strength on Wednesday, but following some brisk selling in the closing minutes, ended the day's session with just a small gain.
RTTNews | 2h 23min ago
European Stocks Close Weak On Tariff Concerns, Some Weak Earnings Updates

European Stocks Close Weak On Tariff Concerns, Some Weak Earnings Updates

European stocks closed weak on Wednesday as concerns about tariffs, and reports that U.S. President Donald Trump will sack Fed Chair Jerome Powell sometime soon, hurt sentiment. Investors also digested a slew of corporate earnings updates that fell short of expectations.
RTTNews | 2h 39min ago
U.S. Industrial Production Climbs 0.3% In June, More Than Expected

U.S. Industrial Production Climbs 0.3% In June, More Than Expected

Partly reflecting a surge by utilities output, the Federal Reserve released a report on Wednesday showing industrial production in the U.S. increased by more than expected in the month of June. The Fed said industrial production climbed by 0.3 percent in June, while revised data showed industrial production was unchanged in May.
RTTNews | 5h 22min ago
Bay Street May Open With Positive Bias

Bay Street May Open With Positive Bias

Canadian shares may open with a slightly positive bias on Wednesday, although weak crude oil prices might limit the market's upside. Investors will focus on trade talks and earnings announcements from big name U.S. companies for directional clues.
RTTNews | 6h 46min ago